spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ERT Continues to Drive Innovation in Virtualization for Respiratory Clinical Trials

ERT

Partnership with Inofab Health keeps respiratory trials on track and ensures patient safety during and after COVID-19



PHILADELPHIA – June 25, 2020 – ERT, the global leader in clinical endpoints data collection, today announced a strategic partnership with Inofab Health, a healthcare technology company designing and developing ultrasonic spirometry technology for in-clinic and at-home use. Through the partnership, ERT expands its portfolio of innovative virtual trial solutions to give clinical trial sponsors and contract research organizations (CROs) multiple options for continuing their life-saving research throughout the pandemic and beyond.

Sponsors are looking for reliable data collection methods that enable the continuation of important clinical trials and ensure the safety of clinical trial patients, without requiring them to attend investigative site appointments. ERT is meeting this need with a suite of innovative virtual trial solutions that capture high-quality data from the comfort of patients’ homes.

“We chose to partner with Inofab based on their proven capabilities in meeting respiratory patients’ healthcare needs and their award-winning ultrasonic spirometer, Spirohome,” said Achim Schülke, Executive Vice President of Respiratory Solutions at ERT. “This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.”

Since patients with lung disease are at higher risk for developing more serious complications from the COVID-19 illness, many are likely to avoid clinics or investigative sites to minimize their exposure risk. Together, ERT and Inofab will continue to develop patient-friendly, easy to use solutions enabling at-home, patient-administered testing of the lung, supporting patient comfort and safety while ensuring high-quality data collection to keep respiratory trials on track.

“We’re pleased to partner with ERT and to leverage their extensive experience in delivering the important safety and efficacy data sponsors need when developing new respiratory treatments,” said Kerem Yasar, Chief Technology Officer and Co-Founder of Inofab Health. “Spirohome plays a critical role for endpoint data collection and we’re excited to work with ERT in delivering virtual trial solutions that help clinical trial sponsors continue developing new treatments for the millions of patients living with respiratory disease.”

For more information on ERT’s suite of virtual trial solutions, visit virtualtrials.ert.com.
phone +1 800 961 5004
email eresearch@ert.com
web www.ert.com
email 1818 Market Street, Suite 1000, Philadelphia, PA 19103
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center

Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020: Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated services for combination products, and Nelson Laboratories, LLC, a global provider of lab testing and expert advisory services signed today a partnership agreement that will provide Extractables and Leachables testing at SG US Technology Excellence Center in Boston, MA.
More info >>


White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement